HCHC - HC2 Holdings, Inc.

NYSE - NYSE Delayed Price. Currency in USD
3.2300
+0.1700 (+5.56%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.0600
Open3.2500
Bid3.1100 x 900
Ask3.6900 x 900
Day's Range3.0900 - 3.4625
52 Week Range1.2900 - 4.3300
Volume714,213
Avg. Volume365,009
Market Cap150.358M
Beta (5Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-0.4270
Earnings DateMay 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 28, 2013
1y Target Est8.50
  • GlobeNewswire

    HC2 Broadcasting Announces Carriage of NBCUniversal Owned Television Stations’ LX Network in 15 U.S. Markets

    NEW YORK, June 01, 2020 -- HC2 Broadcasting, the broadcasting subsidiary of HC2 Holdings, Inc. (NYSE: HCHC), announced today the launch of NBCUniversal Owned Television.

  • 3 “Strong Buy” Penny Stocks That Could See Outsized Gains
    TipRanks

    3 “Strong Buy” Penny Stocks That Could See Outsized Gains

    For investors willing to shoulder additional risk, these may be the best of times for buying stocks. Writing at Morgan Stanley, Michael Wilson, the firm’s head of US equity strategy, firmly believes that the signs are bullish, and that current conditions in the markets closely resemble those of March 2009. That was when market turned upwards after the 2008 financial crisis, beginning the longest bull run in history.Wilson wrote, “A significant driver of our bullish call … was based on the equity-risk premium reaching the same levels observed in March 2009. If there’s one thing we’ve learned over the past 10 years, it’s that when risk premium appears you need to grab it before it disappears.”Investors can maximize that premium by finding stocks with the lowest share price and the highest upside potential – in short, by buying into high-rated penny stocks. These equities, typically trading for under $5 per share, offer a minimal cost of entry – and can sometimes show triple digit upside potential. We’ve used the TipRanks database to pull up the details on three such opportunities. All three have received enough support from Wall Street analysts to earn a “Strong Buy” consensus rating. Not to mention each boasts substantial upside potential of over 100%.Organogenesis Holdings (ORGO)Organogenesis’ subsidiaries operate in the world of medical tech, developing new technologies in two markets: wound care, and surgical and sports medicine.Despite a sharp increase in earnings losses during the first quarter, Organogenesis had good news to report. Top-line revenue came in at $61.7 million, modestly beating the forecast but growing 8% year-over-year. Revenues grew substantially in both the wound care and surgical and sports medicine segments. The company finished the quarter with $46.9 million in cash on hand.Organogenesis returned to public trading at the beginning of last year, after 16 years as a private company. Like many high-tech medical companies, it has not yet turned a profit – but it does have exciting prospects for successful products in potentially lucrative sales fields.This potential lies behind 5-star analyst Richard Newitter’s comments. In his report for Leerink, Newitter writes, “As a relatively new public company, we believe ORGO has yet to be fully “discovered” by investors with a below-peer valuation that in our view is highly dislocated from the company’s longer-term sales growth prospects, healthy end-markets, and a scalable long term 70%+ GM business. Ultimately, as investors increasingly come to appreciate ORGO’s potential for sustainable DD top-line growth & increased profitability prospects into the out-years, we think the multiple will expand driving shares higher.”In line with his upbeat outlook, Newitter rates ORGO shares a Buy, and his $7 price target implies a 112% upside potential. In short, the analyst believes that now is the time for investors to get in at the ground level. (To watch Newitter’s track record, click here)All in all, Wall Street analysts are unanimous in their endorsement of the shares. Organogenesis stock has been endorsed with "buy" ratings by all four of the analysts who have voiced an opinion over the past year. Meanwhile, the consensus estimate of analysts is that ORGO, currently trading at $3.33, should rise over 120% to hit $7.50 within a year. (See Organogenesis stock analysis on TipRanks)Usio, Inc. (USIO)Next up on our list is a tech company, Usio. This company provides payment solutions for merchants and billers, offering credit, debit, and prepaid card processing, and automated clearing house payment platforms. Usio aims to combine card issuing and merchant payment processing options into a ‘one stop shop’ platform.A small-cap company, with a market capitalization of just $32 million, Usio is nevertheless in a strong position despite the coronavirus market disruptions. While markets have lost heavily in the current bear cycle – even accounting for the rally we’re experiencing – USIO shares have outperformed and are trading above their late-February levels. The company reported an 18% growth in revenues for Q1 2020, to $7.8 million, along with steady progress towards break-even cash flow. Usio ended the quarter with $1.7 million in cash on hand. These positive results came despite a net loss in Q1 – but it is important to note that Usio’s Q1 losses were 50% lower than in Q4, and beat the quarterly expectation by 14%.Usio has also been able to take advantage of Congressional stimulus funds. The company qualified for a CARES Act loan of $814,000. The loan comes with generous repayment terms, and provides Usio with needed liquidity to meet the coronavirus crisis.Ladenburg Thalmann analyst Jon Hickman sees a clear path forward for Usio, writing, “…we believe Usio's current market valuation is not reflective of the value of the company’s growing presence in the digital payments space. Given the expected increasing revenue growth and future earnings potential, we believe the company should be valued more in line with its current and potential earnings growth.”Hickman’s Buy rating is bolstered by his $4.50 price target, which indicates confidence in a robust 142% one-year upside potential. (To watch Hickman’s track record, click here)USIO shares have a Strong Buy analyst consensus rating, and it is unanimous. All three of the analysts who have reviewed this stock recently have come down with Buy recommendations. The shares are selling for just $1.75, and the average price target matches Hickman’s $4.50. The upside potential, 142%, implies that this stock will more than double in the coming year. (See Usio analyst ratings on TipRanks)Ramaco Resources (METC)The last stock on our list is Ramaco, a coal mining company operating in Pennsylvania, Virginia, and West Virginia. The company focuses its output on metallurgical coal, a grade used to produce the refined coke that is required in the steel industry.Even with economic activity greatly reduced in Q1 by the responses to the coronavirus crisis, Ramaco reported a quarterly profit. The 5-cent EPS came in 67% over the forecast. Earnings weren’t the only positive in the Q1 report. Revenue came in at $41.9 million, or 2.5% over the estimates.Ramaco’s main sales theater is the eastern US – but demand there has collapsed due to the economic shutdowns. The company has countered this by turning to foreign customers and accepting aid through the Congressionally passed Paycheck Protection Program. The $8.4 million PPP loan has shored up the company’s liquidity position, and allowed it to resume operations at two mines which were idled on April 1.Lucas Pipes, covering the industry and Ramaco stock for B Riley FBR, notes, “…management pointed to a number of marketing successes in the first quarter, including renewing a relationship with a major European customer, their first test shipment to Asia, and a notice that their product was approved for purchase by major integrated steel mills in Brazil [...] While we currently see investors focus on liquidity, then capital returns, and growth opportunities last, we regard these growth projects as long-term options when market conditions improve.”These successes put Ramaco in a solid position to move forward, and Pipes rates the stock a Buy. His price target, at $8, implies a sky-high 221% upside potential this year. (To watch Pipes’ track record, click here)It’s not often that the analysts all agree on a stock, so when it does happen, take note. Ramaco’s Strong Buy consensus rating is based on a unanimous 4 Buys. The stock’s $5.25 average price target suggests a potential upside of 103% and a change from the current share price of $2.56. (See Ramaco stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Usio, Inc. (NASDAQ:USIO) Just Reported, And Analysts Assigned A US$3.90 Price Target
    Simply Wall St.

    Usio, Inc. (NASDAQ:USIO) Just Reported, And Analysts Assigned A US$3.90 Price Target

    Usio, Inc. (NASDAQ:USIO) investors will be delighted, with the company turning in some strong numbers with its latest...

  • GlobeNewswire

    HC2 Holdings and MG Capital Announce Settlement Agreement and Plan to Reconstitute Board of Directors

    HC2 Holdings, Inc. (“HC2” or the “Company”) (HCHC), a diversified holding company, and MG Capital Management, Ltd. (together with Percy Rockdale LLC and Rio Royal LLC, “MG Capital”) today announced a settlement agreement to reconstitute the Board of Directors (the “Board”). The agreement provides for the immediate appointment of four new members – Kenneth S. Courtis, Avram A. “Avie” Glazer, Michael Gorzynski and Shelly C. Lombard – who will also stand for election on HC2’s seven-member slate at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) to be held on Wednesday, July 8, 2020.

  • HC2 Holdings Sells 30% Stake in Huawei Marine, To Lower Debt
    Zacks

    HC2 Holdings Sells 30% Stake in Huawei Marine, To Lower Debt

    HC2 Holdings' (HCHC) divestment of its 30% stake in Huawei Marine will enable it to lower outstanding senior notes by $50 million. Deleveraging actions and solid capital structure are its priorities for the near term.

  • GlobeNewswire

    HC2 Holdings Completes Sale of Interest in HMN Joint Venture

    NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- HC2 Holdings, Inc. (“HC2” or the “Company”) (NYSE: HCHC), a diversified holding company, announced today that the Company, through an indirect subsidiary in which HC2 holds an approximate 73% equity interest, has completed the first close of the sale of its 30% stake in Huawei Marine Networks Co., Limited (“HMN”), its 49%-owned equity investment, to Hengtong Optic-Electric Co Ltd (“Hengtong”). 

  • Thomson Reuters StreetEvents

    Edited Transcript of HCHC earnings conference call or presentation 11-May-20 9:00pm GMT

    Q1 2020 HC2 Holdings Inc Earnings Call

  • HC2 Holdings (HCHC) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    HC2 Holdings (HCHC) Reports Q1 Loss, Misses Revenue Estimates

    HC2 Holdings (HCHC) delivered earnings and revenue surprises of -73.47% and -3.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    HC2 Holdings Reports First Quarter 2020 Results

    - First Quarter 2020 Consolidated Net Revenue of $444.8 Million -- Completes Sale of Global Marine Group, Reducing Debt -- COVID-19 Business Update - NEW YORK, May 11, 2020 --.

  • GlobeNewswire

    HC2 Holdings Advises Stockholders to Revoke Their Consents to Percy Rockdale’s Proposals

    HC2 Holdings, Inc. (“HC2” or the “Company”) (HCHC), a diversified holding company, today reminded stockholders to review HC2’s extensive board refreshment, stockholder engagement and voluntary compensation reductions, before making a considered judgment on Board composition at the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”). The Company strongly advises that stockholders refrain from committing to a hasty decision and return the WHITE consent revocation card to revoke their consent to Percy Rockdale’s unnecessary consent solicitation, and recommends that stockholders support HC2’s slate of independent, experienced and highly-qualified directors at the forthcoming 2020 Annual Meeting mere weeks away.

  • GlobeNewswire

    DBM Global Inc., a HC2 Portfolio Company, to Pay Cash Dividend

    NEW YORK, May 04, 2020 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that its operating subsidiary DBM Global Inc. (OTC:DBMG), a family of.

  • GlobeNewswire

    DBM Global to Pay Cash Dividend

    PHOENIX, May 04, 2020 -- DBM Global Inc. (OTC: DBMG), a family of companies providing fully integrated steel construction services, and an operating subsidiary of HC2 Holdings,.

  • GlobeNewswire

    HC2 Holdings to Announce First Quarter 2020 Financial Results

    NEW YORK, May 04, 2020 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it will release its financial results for the first quarter 2020.

  • GlobeNewswire

    HC2 Holdings Announces Date Of 2020 Annual Meeting Of Stockholders And Additional Board Nominees

    HC2 Holdings, Inc. (“HC2” or the “Company”) (HCHC), a diversified holding company, today announced that the Company’s 2020 Annual Meeting of Stockholders (the “2020 Annual Meeting”) will be held on Wednesday, July 8, 2020, at a time and place to be subsequently determined. Stockholders of record of HC2’s common and preferred stock, in each case, outstanding and entitled to vote as of the close of business on May 22, 2020 will be entitled to vote at the 2020 Annual Meeting and any continuations, adjournments or postponements thereof.

  • Business Wire

    MG Capital Announces That All Three Independent Proxy Advisory Firms Have Endorsed Its Case for Wholesale Change in HC2’s Boardroom

    MG Capital Management, Ltd. (together with Percy Rockdale LLC, the nominating stockholder, and its affiliates, "MG Capital" or "we"), today announced that Egan-Jones Proxy Services ("Egan-Jones"), a leading independent proxy advisory firm, has endorsed its case for wholesale change at HC2 Holdings, Inc. (NYSE: HCHC) ("HC2" or the "Company"). Egan-Jones recommends that stockholders vote to CONSENT to all actions on the GREEN Consent card, including the election of all six of MG Capital’s highly-qualified and independent nominees – George Brokaw, Kenneth Courtis, Michael Gorzynski, Robin Greenwood, Liesl Hickey and Jay Newman – to HC2’s Board of Directors (the "Board"). Egan-Jones’ endorsement to remove each and every individual on the Board comes just hours after Glass, Lewis & Co., LLC ("Glass Lewis") announced its unanimous support of our entire slate, in addition to support for our case for change from Institutional Shareholder Services Inc. ("ISS") last week.

  • Business Wire

    MG Capital Announces Glass Lewis’ Recommendation to Remove the Entire HC2 Board and Elect All Six of MG Capital’s Director Nominees

    MG Capital Management, Ltd. (together with Percy Rockdale LLC, the nominating stockholder, and its affiliates, "MG Capital" or "we"), today announced that Glass, Lewis & Co., LLC ("Glass Lewis"), a leading independent proxy advisory firm, has endorsed its case for wholesale change at HC2 Holdings, Inc. (NYSE: HCHC) ("HC2" or the "Company"). Glass Lewis recommends that stockholders vote to "CONSENT" to all actions on the GREEN consent card, including the election of all six of MG Capital’s highly-qualified and independent nominees – George Brokaw, Kenneth Courtis, Michael Gorzynski, Robin Greenwood, Liesl Hickey and Jay Newman – to HC2’s Board of Directors (the "Board"). Learn more about our nominees and how to CONSENT on the GREEN card at www.ABetterHC2.com.

  • Business Wire

    MG Capital Comments on HC2’s Desperate, Last-Minute Announcement Regarding Philip Falcone’s Excessive Compensation

    MG Capital Management, Ltd. (together with Percy Rockdale LLC, the nominating stockholder, and its affiliates, "MG Capital" or "we"), a significant stockholder of HC2 Holdings, Inc. (NYSE:HCHC) ("HC2" or the "Company"), which collectively with the other participants in its solicitation beneficially owns more than 6% of the Company’s outstanding shares, today commented on HC2’s announcement regarding CEO Philip Falcone’s decision to not receive incentive compensation until the Company’s stock price reaches $7.50 per share. Additional important information is available for stockholders at www.ABetterHC2.com.

  • GlobeNewswire

    HC2 Holdings CEO Phil Falcone Voluntarily Commits to Forgo Bonus Until HC2 Stock Price Reaches $7.50

    HC2 Holdings, Inc. (“HC2” or the “Company”) (HCHC), a diversified holding company, today announced that Philip Falcone, HC2’s Chief Executive Officer and President, has voluntarily committed to forgoing any potential bonus payments in respect of 2020 performance or any future year performance until the stock price reaches an average trading price of at least $7.50 per share over a 30 trading day period. “The Board is very pleased with Phil’s extraordinary commitment to creating stockholder value,” said Warren Gfeller, Interim Chairman of the HC2 Board of Directors.

  • Business Wire

    MG Capital Encourages Stockholders to Avoid Being Misled by HC2’s Attempts to Rewrite History

    MG Capital Management, Ltd. (together with Percy Rockdale LLC, the nominating stockholder, and its affiliates, "MG Capital" or "we"), a significant stockholder of HC2 Holdings, Inc. (NYSE: HCHC) ("HC2" or the "Company"), which collectively with the other participants in its solicitation beneficially owns more than 6% of the Company’s outstanding shares, today commented on HC2’s latest attempt to rewrite history. Additional important information is available for stockholders at www.ABetterHC2.com.

  • GlobeNewswire

    HC2 Holdings Sets The Record Straight As Percy Rockdale’s Charade Continues

    Company Shares Presentations Addressing False and Misleading Narratives Being Advanced by Percy Rockdale in an Effort to Distract Stockholders from its Short-Term and.

  • Is HC2 Holdings, Inc.'s (NYSE:HCHC) CEO Being Overpaid?
    Simply Wall St.

    Is HC2 Holdings, Inc.'s (NYSE:HCHC) CEO Being Overpaid?

    In 2014, Phil Falcone was appointed CEO of HC2 Holdings, Inc. (NYSE:HCHC). This analysis aims first to contrast CEO...

  • Business Wire

    MG Capital Announces ISS Supports Case for Significant Change at HC2

    MG Capital Management, Ltd. (together with Percy Rockdale LLC, the nominating stockholder, and its affiliates, "MG Capital" or "we"), a significant stockholder of HC2 Holdings, Inc. (NYSE: HCHC) ("HC2" or the "Company"), which collectively with the other participants in its solicitation beneficially owns more than 6% of the Company’s outstanding shares, today announced that Institutional Shareholder Services ("ISS"), a leading proxy advisory firm, has endorsed its case for significant change at HC2 by recommending for the immediate removal of Chief Executive Officer Philip Falcone and two other legacy members of HC2’s Board of Directors (the "Board"). Stockholders who agree that wholesale change is needed atop HC2 should consent on the GREEN card for all six of MG Capital’s highly-qualified, independent director nominees. Learn about our case for change and how to consent at www.ABetterHC2.com.

  • GlobeNewswire

    HC2 Holdings Issues Statement On ISS Report

    HC2 URGES STOCKHOLDERS TO OPPOSE PERCY ROCKDALE’S PROPOSALS AND AGREES WITH ISS RECOMMENDATION TO VOTE AGAINST GORZYNKSI, GREENWOOD AND HICKEY ISS Questions the Viability of.

  • GlobeNewswire

    Pansend Life Sciences' Portfolio Company, R2 Technologies, Receives Additional $10 Million Equity Investment From Huadong Medicine Company Limited

    HC2 Holdings, Inc. (“HC2”) (HCHC), a diversified holding company, announced today that R2 Technologies (“R2”), a privately-held portfolio company within HC2’s Pansend Life Sciences (“Pansend”) subsidiary, has received an additional $10 million equity investment from Huadong Medicine Company Limited (“Huadong”) (000963.SZ), R2’s exclusive distributor in the China/Asia-Pacific market. This represents the second tranche of Huadong’s investment in R2 at an approximate post-money valuation of $90 million. Proceeds from the new equity investment in R2 are being utilized to commercialize R2’s FDA-approved revolutionary CryoAesthetic technology, which promises physicians a new way to treat aesthetic and medical skin conditions.